Optimization of pathogenetic treatment of secretory diarrhea in infants by Ількун, І.Я. & Гарас, Микола Нестирович
MIHICTEPCTBO OXOPOHl/1 3AOPOB'fl YKPA"iHlll 
BIil �111 Ll1 A E P)KAB H 111 Ll1 HAB 4AJ1 b H 111 Ll1 3AK11AA YKPA"iH 111 
«6YKOBll1HCbKll1Ll1 AEP)KABHll1Ll1 MEA1114Hlllll1 YHIBEPClllTET» 
2016 
BCEYKPA'iHCbKv1� ME.Qv14Hv1� }l{YPHAJl MOJ10.Qv1X 84EHv1X 
"IEPHIBU.1 
2016 
Міністерство охорони здоров'я України
Вищий державний навчальний заклад України 
"Буковинський державний медичний університет"
ХИСТ
2016, випуск 18,  
Всеукраїнський медичний журнал молодих вчених
 Заснований у 2000 році
Головний редактор
д.мед.н., проф. Т.М.Бойчук
Заступник головного редактора
к.мед.н., доц. О.А.Тюлєнєва
Відповідальні секретарі:
С.Л. Говорнян
д. мед. н., проф. І.С. Давиденко,
д. мед. н., проф. Ю.Є. Роговий,
д. мед. н., проф. В.К. Тащук,
д. мед. н., проф. О.І. Федів,
д. мед. н., проф. О.С. Федорук,
д. мед. н., проф. Р.Є. Булик,
д. мед. н., проф. Н.В. Пашковська,
к. мед. н., доц. М.П. Антофійчук.
Адреса редакції: 58002, Чернівці, пл. Театральна, 2, СНТ БДМУ.
Тел./факс: (03722) 3-52-62; (0372) 55-17-39. E-mail: snt@bsmu.edu.ua
Повнотекстова версія журналу представлена на сайті: http://bim.co.ua/
Чернівці, 2016
«ХИСТ» Всеукраїнський журнал студентів та молодих вчених випуск 18, 2016
Gvasalia T.
MANAGING ANEMIA IN CHRONIC KIDNEY DISEASE CHILDREN
Tbilisi State Medical University, Tbilisi, Georgia
Departement of Pediatrics
(scientific advisor - M.D. Davitaia T.)
Chronic Kidney Disease (CKD) is significant medical problem progressing to End-stage Renal Disease (ESRD). Anemia occurs in 
30% of CKD patients. It increases cardiovascular risk and is one of the leading causes of mortality. In CKD associated anemia, 
elevated hepcidin and vitamin D deficiency are common. Hepcidin causes intracellular sequestration of iron and increases the risk of 
anemia.
Therefore, some studies have shown possible role of vitamin D in regulating iron level and treating anemia. Is some clinical trials 
cultured hepatocytes and monocytes were treated with prohormone 25-hydroxyvitamin D or active 1,25-dihydroxyvitamin D and the 
result was lowered hepcidin mRNA by 0,5 fold. 1,25-dihydroxyvitamin binds to vitamin D receptor thus decreasing hepcidin level and 
increasing expression of intracellular iron marker, ferritin, which stores iron, deposits it and transports it to the required areas 
Erythropoiesis stimulating agents (ESA) seem to be used for managing anemia as they are stimulating production of red blood cells, 
but some studies indicate to low potential of this group of drugs, because of ESA hyporesponsiveness and several side effects such 
as hypertension, increased risk of thrombosis and other cardiovascular problems.In conclusion, vitamin D is important for regulation 
hepcidin - ferroportin balance, thus  facilitating iron egress and ameliorating CKD associated anemia.
To test this hypothesis, vitamin D mediated changes can be compared using in vitro and in vivo models and studied 
retrospectively to determine the further means of managing anemia in CKD patients.
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The aim of the research was to establish clinical efficacy of oral rehydration therapy using 3rd oral rehydration generation solution 
in the treatment of secretory diarrhea in infants.
To achieve this aim examined 116 infants, randomly selected, with acute gastroenteritis and were admission to the hospital with 
signs of dehydration as a result of secretory diarrhea. The mean age of patients was 9,2±0,8 months. Among 73 evaluable patients 
(67,5%) children (I clinical group) to receive 3rd generation oral rehydration solution and 35 (32,4 %) patients (II clinical group) 
received other rehydration solutions. Dynamic assessment of the clinical severity of the infants made within 7 days of hospitalization.
Used as a major component 3rd generation oral rehydration solution showed significantly faster such signs: normalization of body 
temperature, frequency and character of bowel movements, disappearance of vomiting. Dynamic scoring the severity of the patients 
examined shows that, starting from the 3rd day of hospitalization children who received 3rd generation oral rehydration solution 
differed significantly better clinical performance.
In the case of 3rd generation oral rehydration solution in infants average gain in body weight in them was 103,5±10,2 g to 
78,5±8,7 g (P=0.05).
In children treated with 3rd generation oral rehydration solution compared to representatives of the 2nd clinical group, the odds 
ratio to limit oral rehydration alone (without infusion therapy) was 3,7 (95 % CI 0,4–38,9) with an absolute risk to avoid the need for 
infusion therapy - 11%.
Use for the purpose of oral rehydration therapy 3rd generation oral rehydration solution is characterized by a relatively positive 
clinical dynamics as a likely shorter term diarrhea, earlier normalization of body temperature, cessation of vomiting and best rates to 
restore the lost weight. Efficacy of oral rehydration using the 3rd generation oral rehydration solution increases the chances of 
avoiding the need of infusion therapy in 3,7 times.
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